ES2893374T3 - Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativos - Google Patents
Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativosInfo
- Publication number
- ES2893374T3 ES2893374T3 ES15710328T ES15710328T ES2893374T3 ES 2893374 T3 ES2893374 T3 ES 2893374T3 ES 15710328 T ES15710328 T ES 15710328T ES 15710328 T ES15710328 T ES 15710328T ES 2893374 T3 ES2893374 T3 ES 2893374T3
- Authority
- ES
- Spain
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- equiv
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1NC(*)*=C(*)C1C(O)=O Chemical compound *C1NC(*)*=C(*)C1C(O)=O 0.000 description 30
- XNGSKTVUFVGKOF-UHFFFAOYSA-N CCC(C)(C#N)OC(N(CC1)CC1N)=O Chemical compound CCC(C)(C#N)OC(N(CC1)CC1N)=O XNGSKTVUFVGKOF-UHFFFAOYSA-N 0.000 description 1
- HJRZEXYEOXVFGH-UHFFFAOYSA-N CN(CC1)CCN1c1cc(Br)ccc1 Chemical compound CN(CC1)CCN1c1cc(Br)ccc1 HJRZEXYEOXVFGH-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- CPULIKNSOUFMPL-UHFFFAOYSA-N Cc1c[s]c(C)c1 Chemical compound Cc1c[s]c(C)c1 CPULIKNSOUFMPL-UHFFFAOYSA-N 0.000 description 1
- IITRFUUPLFKKHH-UHFFFAOYSA-N O=S(C1CC1)(c1cc(Cl)cc(Cl)c1)=O Chemical compound O=S(C1CC1)(c1cc(Cl)cc(Cl)c1)=O IITRFUUPLFKKHH-UHFFFAOYSA-N 0.000 description 1
- FMDBLYJSBIGAQS-UHFFFAOYSA-N OCCNCCOc1ccccc1 Chemical compound OCCNCCOc1ccccc1 FMDBLYJSBIGAQS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461942956P | 2014-02-21 | 2014-02-21 | |
| PCT/US2015/016928 WO2015127284A2 (en) | 2014-02-21 | 2015-02-20 | Antimitotic amides for the treatment of cancer and proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2893374T3 true ES2893374T3 (es) | 2022-02-08 |
Family
ID=52684675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15710328T Active ES2893374T3 (es) | 2014-02-21 | 2015-02-20 | Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativos |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10016398B2 (OSRAM) |
| EP (1) | EP3107909B1 (OSRAM) |
| JP (1) | JP6506313B2 (OSRAM) |
| KR (1) | KR102420508B1 (OSRAM) |
| CN (2) | CN106068263A (OSRAM) |
| AU (1) | AU2015218775C1 (OSRAM) |
| BR (1) | BR112016019161B1 (OSRAM) |
| CA (1) | CA2940237C (OSRAM) |
| ES (1) | ES2893374T3 (OSRAM) |
| IL (1) | IL247293B (OSRAM) |
| MX (1) | MX390530B (OSRAM) |
| RU (1) | RU2713179C2 (OSRAM) |
| SG (2) | SG10202000590SA (OSRAM) |
| WO (1) | WO2015127284A2 (OSRAM) |
| ZA (1) | ZA201606471B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| CA2940237C (en) * | 2014-02-21 | 2023-03-07 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
| CN106727583A (zh) * | 2016-12-12 | 2017-05-31 | 范旭升 | 一种治疗舒张性心衰的药物组合物 |
| WO2019014460A1 (en) * | 2017-07-12 | 2019-01-17 | The Brigham And Women's Hospital, Inc. | MOLECULES ENHANCING EAAT2 |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| US6689779B2 (en) | 2000-06-05 | 2004-02-10 | Dong A Pharm. Co., Ltd. | Oxazolidinone derivatives and a process for the preparation thereof |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0209715D0 (en) * | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| WO2006002896A1 (en) * | 2004-06-30 | 2006-01-12 | Novartis Ag | Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors |
| US20090156646A1 (en) * | 2005-08-11 | 2009-06-18 | Takeda Pharmaceutical Company Limited | Pyridylphenol compound and use thereof |
| WO2007089904A2 (en) * | 2006-01-31 | 2007-08-09 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| ATE524465T1 (de) | 2006-11-17 | 2011-09-15 | Glaxosmithkline Llc | 2-carboxy-thiophen-derivate als viruzide |
| WO2008125839A2 (en) * | 2007-04-12 | 2008-10-23 | Piramed Limited | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase |
| WO2010039236A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| HRP20150104T1 (xx) * | 2009-09-11 | 2015-03-13 | Amgen, Inc. | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-thienil)-1-ftalazinamin za primjenu u tretmanu kancera rezistentnog na antimitotiäśke agense |
| WO2011139489A2 (en) * | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| WO2011142151A1 (ja) * | 2010-05-14 | 2011-11-17 | シャープ株式会社 | 携帯型情報端末およびその制御方法 |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CN103380117A (zh) * | 2011-01-21 | 2013-10-30 | Abbvie公司 | 激酶的吡啶酰胺抑制剂 |
| EP2673264A1 (en) * | 2011-02-10 | 2013-12-18 | Syngenta Participations AG | Microbiocidal pyrazole derivatives |
| JP5985611B2 (ja) * | 2011-05-03 | 2016-09-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための化合物 |
| WO2013063385A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| CA2940237C (en) * | 2014-02-21 | 2023-03-07 | Frost Biologic, Inc. | Antimitotic amides for the treatment of cancer and proliferative disorders |
-
2015
- 2015-02-20 CA CA2940237A patent/CA2940237C/en active Active
- 2015-02-20 RU RU2016135555A patent/RU2713179C2/ru active
- 2015-02-20 SG SG10202000590SA patent/SG10202000590SA/en unknown
- 2015-02-20 ES ES15710328T patent/ES2893374T3/es active Active
- 2015-02-20 CN CN201580009889.2A patent/CN106068263A/zh active Pending
- 2015-02-20 BR BR112016019161-7A patent/BR112016019161B1/pt active IP Right Grant
- 2015-02-20 CN CN202210190090.XA patent/CN114634483B/zh active Active
- 2015-02-20 JP JP2016570919A patent/JP6506313B2/ja active Active
- 2015-02-20 KR KR1020167026016A patent/KR102420508B1/ko active Active
- 2015-02-20 EP EP15710328.4A patent/EP3107909B1/en active Active
- 2015-02-20 MX MX2016010877A patent/MX390530B/es unknown
- 2015-02-20 WO PCT/US2015/016928 patent/WO2015127284A2/en not_active Ceased
- 2015-02-20 US US15/120,470 patent/US10016398B2/en active Active
- 2015-02-20 SG SG11201606869TA patent/SG11201606869TA/en unknown
- 2015-02-20 AU AU2015218775A patent/AU2015218775C1/en active Active
-
2016
- 2016-08-16 IL IL247293A patent/IL247293B/en active IP Right Grant
- 2016-09-20 ZA ZA2016/06471A patent/ZA201606471B/en unknown
-
2018
- 2018-06-29 US US16/024,407 patent/US10772872B2/en active Active
-
2020
- 2020-09-03 US US17/011,589 patent/US11129813B2/en active Active
-
2021
- 2021-09-13 US US17/473,364 patent/US12383533B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2906785T3 (es) | Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones | |
| DE69715888T2 (de) | Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel | |
| DE69715439T2 (de) | Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel | |
| ES2893374T3 (es) | Amidas antimitóticas para el tratamiento de cáncer y de trastornos proliferativos | |
| RU2537319C2 (ru) | Способы изготовления и назначение деривата sphaelactone и его композитные лекарства | |
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| WO2012000304A1 (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| KR20120083292A (ko) | 글리신 화합물 | |
| JP2009503060A (ja) | Ｎ−フェニル−２−ピリミジン−アミン誘導体及びそれの調製のための工程 | |
| ES2744597T3 (es) | Compuestos de heteroarilo con una unidad acíclica como puente | |
| CN108473504B (zh) | 新型二氢吡喃并嘧啶酮衍生物及其用途 | |
| US20200325131A1 (en) | Novel crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application | |
| ES2736098T3 (es) | Derivados de 2-aminotiazol o sal de los mismos como ligandos muscarínicos M3 para el tratamiento de enfermedades de la vejiga | |
| HK1232858B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| CA2511021C (en) | Substituted benzodioxepines | |
| CN111171044B (zh) | 一种噻吩并嘧啶类化合物及其医药用途 | |
| US20240317717A1 (en) | Sulfonamide compounds and the use thereof in the treatment of cancer | |
| WO2018098250A1 (en) | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof |